WTO to discuss cross-border movement of COVID-19 vaccine, regulatory transparency
The World Trade Organization (WTO) is set to hold talks to contribute to improved public and policymaker understanding of the operation of global COVID-19 vaccine supply chains, the cross-border movement of vaccine inputs, and the need for greater regulatory transparency and convergence.
The WTO will be discussing these issues at a technical symposium slated for 29 June, 2021. The event will map vaccine production and trade and discuss trade measures that support or constrain the achievement of the rapid scale-up of vaccine production and distribution. Discussions will also encompass diagnostics, therapeutics and other COVID-19-related medical goods.
The technical symposium on “COVID-19 vaccine supply chain and regulatory transparency” is a follow-up to the WTO-organized meeting on “COVID-19 and Vaccine Equity: What Can the WTO Contribute?” held on 14 April.
On that occasion, Director-General Ngozi Okonjo-Iweala called on WTO members, vaccine manufacturers and international organizations to address trade-related obstacles to COVID-19 vaccine production scale-up in order to hasten the end of the pandemic and accelerate global economic recovery.
Speaking to G20 leaders and the heads of international organizations on 21 May, DG Okonjo-Iweala also stressed the key role WTO members can play in fostering greater equity in the global distribution of COVID-19 vaccines by lowering supply chain barriers, fully using existing production capacity, and addressing issues related to intellectual property, access and innovation.
Mapping vaccine manufacturing and trade as well as cross-border movement of vaccine inputs will feature in the discussions of the symposium. Participants will look at the latest projections on COVID-19 vaccine manufacturing output, the impact of supply chain mapping exercises and possible policy responses to supply chain bottlenecks as reported by vaccine producers. They will also discuss what can be done to improve the monitoring and facilitation of cross-border movement of vaccine inputs.
The symposium will include a session on promoting transparency and convergence in the regulatory landscape, with an emphasis on how transparency in the regulatory approval process can be strengthened and on how international cooperation can contribute to manufacturing, approving and disseminating vaccines, therapeutics and diagnostics. The final session will look beyond vaccines and encompass a wider spectrum of health technologies, including diagnostics and therapeutics, as well as other medical products.
Amaka E. Nliam
